Marina Parra-Robert1, Víctor Molina Santos2, Silvia Miró Canis3, Xavier Filella Pla1, Josep Maria Augé Fradera1, Rafael Molina Porto4. 1. Oncobiology Unit, Department of Biochemistry and Molecular Genetics, Biomedical Diagnostic Center (CDB), Hospital Clínic, Barcelona, Spain. 2. Department of Surgery, Hospital Clínic, Barcelona, Spain. 3. Consorci Laboratori Intercomarcal, Vilafranca del Penedés, Spain. 4. Oncobiology Unit, Department of Biochemistry and Molecular Genetics, Biomedical Diagnostic Center (CDB), Hospital Clínic, Barcelona, Spain RMOLINA@clinic.cat.
Abstract
BACKGROUND/AIM: Approximately 10% of patients are unable to synthesize CA 19.9 (Lewis-negative), and these results are erroneously considered false-negatives. The aim of this study was to confirm that CA 19.9 cannot be detected by immunoassays in Lewis-negative patients. MATERIALS AND METHODS: CA 19.9 levels were measured by immunological assays and Lewis phenotype was determined by the haemagglutination reaction. RESULTS: Patients with Lewis phenotype (a+b-) or (a-b+) had significantly higher CA 19.9 levels than Lewis-negative patients with active cancer (p<0.001), no-evidence of disease (NED) patients (p<0.001) or patients with benign disease (p<0.001). Ninenty-four percent of patients (33/35) with undetectable CA 19.9 had a Lewis-negative phenotype. Additionally, 94.7% (34/36) of patients with Lewis-negative phenotypes had undetectable CA 19.9 serum levels. CONCLUSION: Patients with undetectable CA 19.9 serum levels tend to be Lewis-negative, and CA 19.9 is not useful in diagnosis or follow-up. Copyright
BACKGROUND/AIM: Approximately 10% of patients are unable to synthesize CA 19.9 (Lewis-negative), and these results are erroneously considered false-negatives. The aim of this study was to confirm that CA 19.9 cannot be detected by immunoassays in Lewis-negative patients. MATERIALS AND METHODS: CA 19.9 levels were measured by immunological assays and Lewis phenotype was determined by the haemagglutination reaction. RESULTS:Patients with Lewis phenotype (a+b-) or (a-b+) had significantly higher CA 19.9 levels than Lewis-negative patients with active cancer (p<0.001), no-evidence of disease (NED) patients (p<0.001) or patients with benign disease (p<0.001). Ninenty-four percent of patients (33/35) with undetectable CA 19.9 had a Lewis-negative phenotype. Additionally, 94.7% (34/36) of patients with Lewis-negative phenotypes had undetectable CA 19.9 serum levels. CONCLUSION:Patients with undetectable CA 19.9 serum levels tend to be Lewis-negative, and CA 19.9 is not useful in diagnosis or follow-up. Copyright
Authors: Leonel Pekarek; Oscar Fraile-Martinez; Cielo Garcia-Montero; Miguel A Saez; Ines Barquero-Pozanco; Laura Del Hierro-Marlasca; Patricia de Castro Martinez; Adoración Romero-Bazán; Miguel A Alvarez-Mon; Jorge Monserrat; Natalio García-Honduvilla; Julia Buján; Melchor Alvarez-Mon; Luis G Guijarro; Miguel A Ortega Journal: Cancers (Basel) Date: 2022-04-07 Impact factor: 6.575
Authors: Kangjoon Kim; Seung Hyun Yong; Su Hwan Lee; Sang Hoon Lee; Ah Young Leem; Song Yee Kim; Kyungsoo Chung; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Hye-Jeong Lee; Young Ae Kang Journal: Sci Rep Date: 2021-02-02 Impact factor: 4.379
Authors: Daniel Vasile Balaban; Flavius Stefan Marin; George Manucu; Andreea Zoican; Marina Ciochina; Victor Mina; Cristina Patoni; Catalina Vladut; Sandica Bucurica; Raluca Simona Costache; Florentina Ionita-Radu; Mariana Jinga Journal: World J Clin Oncol Date: 2022-07-24
Authors: Jacek Baj; Łukasz Bryliński; Filip Woliński; Michał Granat; Katarzyna Kostelecka; Piotr Duda; Jolanta Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Marzena Furtak-Niczyporuk; Piero Portincasa Journal: Cancers (Basel) Date: 2022-03-15 Impact factor: 6.639